Intelligem Therapeutics Australia

Intelligem Therapeutics is a clinical-stage biotechnology company focused on developing next-generation gene therapies for neurodegenerative disorders. The company utilizes its proprietary Intelligent Gene Modulation (IGM) platform to deliver neurotrophic factors, such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), directly to the central nervous system using Adeno-Associated Virus (AAV) vectors. Their lead programs aim to provide long-term neuroprotection and functional restoration for patients suffering from Alzheimer's disease and Parkinson's disease. Intelligem maintains a strategic presence in Australia to leverage the region's clinical trial infrastructure and research incentives. The company's approach is built upon decades of foundational research into neuronal survival and growth factor delivery.